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Summary
The deficiency or abnormal function of von Willebrand factor (VWF) causes von Willebrand 
disease (VWD), the most frequent inherited bleeding disorder. The laboratory diagnosis of VWD 
can be difficult as the disease is heterogeneous and there is a need of an array of assays to describe 
the phenotype. Basic classification of quantitative (type 1 and 3) and qualitative (type 2) VWD 
variants requires determination of VWF antigenic levels (VWF:Ag) and VWF ristocetin cofactor 
activity assay (VWF:RCo), which assess the capacity of VWF to interact with platelet GPIb-
receptor. VWF:RCo is essential for identifying, subtyping and monitoring VWD, but the assay is 
poorly standardised and many assay protocols do not fulfil the clinical need in all situations. This 
has led to the development of novel activity assays, independent of ristocetin, with enhanced assay 
characteristics. Results from the first independent clinical evaluations are promising showing that 
they are reliable and suitable for VWD diagnosis. The qualitative type 2 VWF deficiency can be 
further divided into four different sub-types (A, B, M and N) with specific assays that explore 
other activities or size distribution of VWF multimers and the methods are discussed here. 
However, in a number of patients it may be difficult to correctly classify the VWD phenotype and 
genetic analysis provides the best option to clarify the disorder through mutation identification.
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Minimum or extensive VWD investigation in clinical routine (G. Castaman)
VWF is a multimeric glycoprotein, synthesized by endothelial cells and megakaryocytes, 
important for platelet adhesion to the subendothelium and for platelet- -platelet interactions, 
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and the specific carrier of factor VIII (FVIII) in plasma. VWD is heterogeneous because 
molecular defects can occur in more than one of the functional domains of the multimeric 
glycoprotein [1, 2]. These functions are explored by an array of laboratory assays, but no 
one reflects the whole spectrum of VWF activities. VWD is classified into three different 
types: partial or complete VWF quantitative deficiency (Type 1 and 3), and qualitative 
deficiency (Type 2). Tests for the correct diagnosis of VWD have to explore the most 
important VWF properties: antigenic level of VWF (VWF:Ag); VWF-platelet GpIb 
interaction (VWF:RCo); VWF-subendothelium-collagen interaction (VWF:CB); VWF-
factor VIII interaction (VWF:FVIIIB); and the capacity of VWF to be organised into 
multimers. FVIII activity (FVIII:C) is also included in the diagnostic work-up because it 
reflects the ability of VWF to protect FVIII from degradation and is a useful complement in 
suspected Type 2N variants.
Prior to laboratory tests, the diagnosis and appropriate classification of VWD requires 
evidence of a bleeding history, usually also present in other family members. The physician 
should take into consideration the practical advantage and the patient perspective of a 
specific diagnosis of VWD in any given patient, avoiding the risk of over-medicalization of 
patients with dubious or mild bleeding history [3]. Written bleeding questionnaires are 
increasingly used to improve the quality of data collection and to reduce both intra- and 
inter-observer variability. When the deficiency of VWF is mild, the risk of bleeding is 
usually small and thus diagnostic efforts are useful especially for patients with a significant 
bleeding history [4,5]. To better define what a significant bleeding history is, a bleeding 
score (BS), accounting for both the number and the severity of the bleeding symptoms, may 
be useful. It has been suggested that a bleeding score ≥3 or ≥5 in males and females 
respectively is a useful cut-off to identify adults in whom it is worthwhile measuring VWF-
related activities [4]. The diagnosis of VWD is then based on the presence of reduced 
VWF:RCo (or VWF:CB) (<40 U/dL), with a further characterization of VWD type based on 
assessment of VWF:Ag, FVIII and multimer pattern. In general, VWF levels <30 U/dL are 
strongly associated with a significant clinical severity and the presence of mutations in the 
VWF gene in type 1 VWD [6,7]. However, levels <40 U/dL with other relatives with similar 
levels is a crucial clue for diagnosis of mild VWD [5], although bleeding history is milder 
and treatment usually rests on avoidance of anti-platelet drugs and use of antifibrinolytics.
Pediatric cases should be evaluated using less stringent criteria, although a recent study 
using the bleeding questionnaire adopted for adults showed that the threshold score for a 
significant bleeding history is ≥2 [8]. Table 1 summarizes a practical multistep approach to 
diagnosis.
VWF:RCo explores the interaction of VWF with platelet glycoprotein Ib/IX/V and is still 
the reference method for measuring VWF activity. Abnormal VWF:RCo/VWF:Ag ratio 
(<0.6) usually indicates the presence of qualitative variants (Type 2). VWF:CB is 
particularly sensitive to VWD variants characterized by the absence of larger VWF 
multimers [9]. VWF:CB is often used as an alternative to multimeric analysis and VWF:CB/
VWF:Ag ratio appears useful for distinguishing between type 1 and 2 VWD [9]. However, 
rare VWD mutations in the A3 domain (p.W1745C and p.S1783A) with normal multimeric 
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pattern show a discrepantly low VWF:CB/VWF:Ag ratio [10]. In some of these patients, the 
diagnosis of VWD could be missed since VWF:RCo level may be borderline.
Ristocetin induced platelet aggregation (RIPA) using patient platelets explores the threshold 
ristocetin concentration which induces aggregation of patient platelet-rich plasma. 
Aggregation occurring at low concentrations identifies type 2B VWD cases, in whom 
desmopressin may cause thrombocytopenia [4]. This test is critical especially when 
multimeric pattern evaluation is not feasible.
The evaluation of closure time (CT) with PFA-100 (Platelet Function Analyzer) allows rapid 
and simple determination of VWF-dependent platelet function at high-shear stress, but this 
system is sensitive and reproducible for severe reduction of VWF, while it has a 
questionable role in screening for mild VWF deficiencies and type 2N VWD [11].
Type 2N VWD is suspected when the FVIII:C level is disproportionately decreased 
compared with normal or subnormal. VWF:Ag and VWF:RCo levels [1,2] As a 
consequence, the FVIII:C/VWF:Ag ratio is reduced (<0.5). The diagnosis relies on 
measurement of the affinity of VWF to FVIII (VWF:FVIIIB), which is markedly decreased.
Recently, an ELISA test for VWF propeptide (VWFpp) has been shown to provide 
information on VWF “function” of some VWD variants, since an increased ratio of steady-
state plasma VWFpp to VWF:Ag identifies patients with increased VWF clearance [12]. 
Typically, they show a severe VWF reduction at baseline and a marked but short-lived VWF 
increase after desmopressin. Thus, measurement of VWFpp in plasma could help identify 
the pathophysiological mechanism responsible for low VWF, predicting response to 
desmopressin. To conclude, while VWF:RCo remains a useful screening test for VWD in 
patients investigated for a bleeding disorder, an array of different tests are required for full 
VWD characterization and should be used in the presence of a clear bleeding history to help 
select the best available treatment.
The VWF ristocetin cofactor assay (A. Hillarp)
The most important assay that probes the capacity of VWF to interact with the GPIb 
receptor on platelets is the VWF:RCo assay. The assay utilizes the antibiotic ristocetin 
sulphate that promotes the VWF-GPIb interaction under static conditions in vitro. Thus, 
VWF:RCo is a non-physiologic assay but it correlates well with the activity and multimeric 
distribution of VWF. However, it is well known that the VWF:RCo assay can be difficult to 
perform and suffers from poor precision and sensitivity, when assay protocols are based on 
manual visual agglutination or platelet aggregometry. The inter-laboratory CV is usually 
30-40% when samples with low VWF content are analysed [13-16] and the limit of 
detection (LOD) is often as high as 10- 20 U/dl, which makes it difficult to use the test to 
identify and differentiate between VWD types with low activities.
In recent years, a number of modifications to the VWF:RCo assay have been published 
involving development of microplate-based assays (i.e. ELISA) or automation on various 
coagulation analysers. One of the driving forces for the diagnostic industry has been to 
produce reagents with improved characteristics that can be automated on common photo-
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optical coagulation analysers. This allows turbidimetric measurements and faster availability 
combined with shorter result turnaround-times. The first commercially available automated 
VWF:RCo assay was performed by Siemens in the late 1990s (BC von Willebrand Reagent) 
and was restricted to Siemens BCS analysers. This assay gave better precision but the LOD 
was still unacceptable high. Nevertheless, this opened up local initiatives by users for 
improvements and applications on different photo-optical analysers. Instrumentation 
Laboratory is another diagnostic company that developed improved variants of the 
VWF:RCo assay. Recombinant wild-type GPIb has been coupled to uniform beads making 
the assay completely platelet-free. The assay comes in two versions, one based on 
turbidimetric detection and the other on chemiluminescence. Recent evaluations showed that 
the new assay protocols were precise and suitable for diagnosis of VWD [17-19].
GPIb-binding assays independent of ristocetin
With specific amino acid substitutions in the GPIb receptor it is possible to obtain constructs 
that bind VWF without need of ristocetin. With these gain-of-function GPIb peptides, novel 
assays based on the ELISA format or particle-based automated assays have successfully 
been developed [20, 21]. It appears also that activity is unaffected by a common VWF gene 
polymorphism known to result in false low VWF:RCo activity [20]. An automated version 
of this assay type was recently commercialised and has gained popularity in regions where it 
has been released. From the European external quality assessment (EQA) organisation 
ECAT, the number of laboratories that use a VWF:RCo assay protocol is steadily declining 
whereas laboratories using alternative activity assays are increasing. The method group for 
assays determining GPIb-binding capacity in the ECAT programme is now divided into two 
activity groups: classical VWF:RCo and novel “VWF activity” and the current number of 
participants is almost equal in the two groups. The majority use the latex VWF activity 
assay from Instrumentation Laboratory or the Innovance VWFAc from Siemens. The former 
is not a “true” activity assay as it relies on a monoclonal antibody that recognizes the 
functional GPIb-binding epitope on VWF. However, the Innovance VWFAc is an assay 
based on the gain-of-function GPIb construct that binds VWF without ristocetin. Despite the 
apparent success, based on the number of users in various EQAs, surprisingly few 
independent evaluations of the novel assays have been published [22]. Compared with the 
VWF:RCo assay, the novel assays have several practical advantages that probably explain 
the fast transition from VWF:RCo to novel activity assays. Moreover, the total number of 
users in the ECAT VWF module has increased recently and it is likely that the simplicity of 
the novel assays encourages less experienced laboratories to include an activity assay in 
their test repertoire.
With the increased diversity of VWF activity assays, other problems arise. First, the 
diagnostic industry provides assays developed for specific instruments that may not be 
available in all countries. Second, the assays themselves may not be approved for clinical 
use in large parts of the world, which is currently the case for the Siemens Innovance 
VWFAc assay, not yet approved by FDA in the US. As a consequence, it is difficult to 
suggest general recommendations on VWD testing that include the novel activity assays. 
Third, the lack of independent evaluation of these assays makes it difficult to ensure that 
they have acceptable sensitivity and specificity for all VWD types. The current ISTH-SSC 
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on VWF has appointed a working party that will compare all available activity tests with the 
VWF:RCo assay and will report during 2014.
In conclusion, the novel VWF activity assays appear to offer significant advantages over the 
VWF:RCo assay. However, lack of independent evaluations on all VWD types does not yet 
allow moving away from old assays to new ones. However, it can be argued that simplicity 
of the novel assays makes it feasible to improve diagnostic capability for VWD in 
laboratories with poor experience of the VWF:RCo assay.
When is genetic analysis an option in VWD? (A. Goodeve)
For many patients with an initial diagnosis of VWD, the testing described above provides 
sufficient information to type and subtype the patient's disorder. As treatment may differ 
with VWD type, it is important to ascertain disease classification, but for a small proportion 
of patients, specific laboratory tests for VWD do not adequately provide this information. 
Genetic analysis can help determine the molecular defect(s) responsible for the patient's 
bleeding and aid classification. Additionally, families with recessively inherited type 3 
VWD may request prenatal diagnosis (PND) and ascertaining mutation(s) in an affected 
individual can facilitate this.
The von Willebrand factor gene (VWF) is relatively large spanning 178 kb of genomic DNA 
with 52 exons encoding the 8.8 kb mRNA and 2813 amino acid VWF monomer. Genetic 
analysis of VWF may include two main processes; 1) analysis of relevant regions of the gene 
for point mutations using Sanger DNA sequencing or a sequence variant-scanning process 
such as confirmation sensitive gel electrophoresis followed by Sanger sequencing to identify 
amplicons with altered behaviour in comparison with wild-type sequence. 2) Analysis of the 
gene for large deletions or duplications of an exon or more using multiplex ligation-
dependent probe amplification (MLPA, MRC Holland) [23] or comparative genomic 
hybridisation [24].
Type 3 VWD
There is generally little doubt about diagnosis of this severe recessive form of VWD, apart 
from its discrimination from severe type 1 disease. Mutation analysis in the index case may 
be requested to determine the causative mutation(s) and to facilitate confirmation in each 
parent's DNA prior to prenatal diagnosis for a further pregnancy. Use of dosage analysis 
plus DNA sequence analysis can identify mutations in upwards of 90% of type 3 VWD 
alleles, but a small proportion of patients remain with only one or no mutations identified 
following these analyses [25]. mRNA analysis may help to identify missing mutations.
PND can be undertaken on chorionic villus samples obtained at 11-13 weeks gestation or on 
amniocentesis samples taken at 16-18 weeks, the latter requiring cell culture to obtain 
sufficient DNA. Analysis of maternal and fetal samples using microsatellite markers in 
different genomic locations can ensure that there is no significant maternal cell 
contamination of the fetal sample analysed (e.g. Promega Powerplex 16) [26]. Investigation 
can be conducted concurrently with fetal mutation analysis.
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Type 2 VWD
Mutations in type 2 VWD are predominantly missense changes affecting specific functional 
domains and can be sought by targeted analysis of exons encoding these domains. This is 
simplest for type 2B and most complex for type 2A.
Patients may be referred for genetic testing when they have a discrepancy between 
VWF:RCo and VWF:Ag (≤0.6) indicating reduced platelet binding activity, but without 
disease type having been clarified. In these cases, exon 28 is the best starting point for 
analysis.
Type 2A—As further work is undertaken to understand the molecular basis of type 2A 
VWD, additional mutation locations are identified. The majority of mutations are found in 
the A2 and A1 domains encoded by exon 28. The D3 domain (exons 22 and 25-27) has 
recently been recognised as the site of >25% of 2A mutations [27]. Rarer mutations are 
found in the cysteine knot (CK, exon 52) and D2 domains (exons 11-17) with occasional 
mutations elsewhere in the gene [28, 29]. Targeted analysis of exon 28 is commonly 
available, but diagnostic laboratories may not analyse further exons.
Type 2B—This gain of function mutation type is characterised by enhanced RIPA. 
Conformational changes induced by the mutation result in spontaneous VWF-glycoprotein 
Ib (GPIb) binding. 2B VWD mutations have a restricted location within the A1 domain 
encoded by the 5’ end of exon 28. Platelet-type pseudo VWD resulting from mutations in 
GP1BA is responsible for a similar phenotype and can be discriminated from 2B by analysis 
of exon 2 of that gene [30].
Type 2M—Mutations can affect either/both binding to GPIb/collagen. They are largely 
located in the A1 domain where they impair binding to GPIb and the A3 domain where they 
may affect binding only to collagen or to both collagen and GPIb Targeted analysis of exons 
28-32 identifies most reported mutations [31].
Type 2N—Patients with this recessively inherited VWD type that mimics mild haemophilia 
A may have reduced FVIII coagulant activity with normal or reduced VWF levels. 
Mutations reduce the binding of FVIII by VWF thus reducing plasma half-life and level. 
Missense mutations responsible predominantly lie in the D’ domain’ encoded by exons 
18-20. There are also reports of missense mutations that influence FVIII binding close to the 
propeptide cleavage site (exon 17) and in the D3 domain (exons 24-25) [29]. Putative 2N 
patients with no mutation in these VWF exons should be investigated for F8 mutations.
Type 1 VWD
Parallel reductions of VWF:RCo and VWF:Ag indicate likely type 1 VWD. Genetic analysis 
may be requested to 1) help understand disease pathogenicity in patients that have 
particularly low VWF levels. Some individuals may be compound heterozygous for two 
different mutations that contribute to their severe reduction in VWF level, whilst others have 
a single dominantly inherited mutation; inheritance pattern has implications for family 
members. 2) Individuals who appear to have a rapid clearance phenotype indicated by 
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elevated VWFpp/VWF:Ag ratio where the majority of mutations reported lie between exons 
25 and 31 [12].
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Table 1
A simplified practical approach to the diagnosis of von Willebrand disease (modified from ref.4)
1. VWD diagnosis should be considered within the context of an appropriate personal and/or familial bleeding history. The use of a 
standardized questionnaire for history collection is advisable to appreciate the severity of the bleeding tendency
2. Other common hemostatic defects should be excluded by performing a platelet count, APTT, PT and PFA-100 (or bleeding time).
3. If personal and/or familial bleeding history is significant, VWF:RCo assay should be carried out. If not possible, VWF:Ag assay or VWF:CB 
assay should be performed. VWF:Ag < 3 U/dL suggests type 3 VWD.
VWF:Ag and VWF:RCo and FVIII:C should be measured on the same sample to assess the presence of a reduced VWF:RCo/VWF:Ag ratio (a 
ratio < 0.6 suggest type 2 VWD) or FVIII:C/VWF:Ag (a ratio < 0.6 suggests type 2N VWD, to be confirmed by binding study of FVIII to 
patient's VWF).
4. If any of these tests is below 40 U/dL, the diagnosis of VWD should be strongly considered.
5. Other family members with a possible bleeding history should be evaluated. Finding another member with bleeding and reduced VWF 
strongly supports the likelihood of diagnosis.
6. Aggregation of patient platelet rich plasma in the presence of increasing concentrations of ristocetin (0.25, 0.5, 1.0 mg/ml, final 
concentration) should be assessed. Aggregation at low concentration (≤ 0.5 mg) suggests type 2B (or platelet type) VWD.
7. Multimer pattern using an intermediate resolution gel should be evaluated. Lack of high molecular weight multimers suggests type 2A and/or 
2B. Presence of full complement of multimers suggests type 1 (or 2N, 2M). Absence of multimers in type 3.
8. VWF genetic analysis could be advisable for differential diagnosis of mild haemophilia A vs 2N VWD in males, haemophilia A carriership 
vs 2N VWD in females and for type 2B VWD vs platelet type-VWD.
9. VWF genetic analysis may be required for prenatal diagnosis in type 3.
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